Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅲ, Randomized, Double-blind and Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Individuals Aged 3 Years and Older

NCT05431725 is registered in ClinicalTrials.gov with Sinovac Biotech Co., Ltd as lead sponsor.

NCT NCT05431725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05431725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅲ, Randomized, Double-blind and Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Individuals Aged 3 Years and Older
Lead sponsor
Sinovac Biotech Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
July 18, 2022
Completion date
July 19, 2023
Enrollment
2,202 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal influenza